Shraddha Narechania is a Respiratory physician. OpenAlex indexes 45 publications with 278 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7710 Mercy Rd Ste 3000
Omaha, NE 681242350
Telephone
402-717-9600Provider last certified this registry record 19 Feb 2026.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Actelion Pharmaceuticals US, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20241 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
96.2%Corticosteroid52.9%Trelegy Ellipta55%Symbicort24%Breztri Aerosphere14%Fluticasone Propionate7%Part D<11 patientsbeta2-Adrenergic Agonist30.7%Albuterol Sulfate Hfa62%Ventolin Hfa38%Part D<11 patients+ 2 more classes in this area
Nervous system
3.8%Aminoketone3.8%Bupropion Hcl Sr100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sample size, model stability, and the interpretation of adjusted effect estimates: correspondence on Moreira et al.
Cost Effectiveness and Resource Allocation
2026 - Do patients with severe community-acquired bacterial pneumonia benefit from systemic corticosteroids?
Cleveland Clinic Journal of Medicine
2025 - Should I start anticoagulation in my patient newly diagnosed with pulmonary hypertension?
Cleveland Clinic Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”